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http://Contents lists available at ScienceDirectEditorialExperimental evidence that preexisting chronic kidney disease is a risk
factor for acute kidney injuryAcute kidney injury (AKI) is deﬁned by a rapid decline in
glomerular ﬁltration rate. AKI is a worldwide health problem;
it has a high mortality rate and can progress toward chronic
kidney disease (CKD). Rates of mortality, morbidity, and
hospitalization following AKI, which is induced by various
medical complications, are higher in patients with CKD [1,2].
CKD is reported in approximately 30% of AKI patients in
intensive care units [2]. Accumulating epidemiological evi-
dence has demonstrated that CKD is a risk factor for the
development of AKI and that the prevalence of CKD is
increasing worldwide [1,2]. However, the role and underlying
mechanisms of CKD in the development of AKI remain unclear
owing to the limitation of clinical studies and the lack of useful
animal models. Furthermore, researchers have not focused on
deﬁning the underlying mechanisms of CKD in the develop-
ment of AKI, most likely because they believe it is biologically
plausible that preinjured organs are more vulnerable to
further injury [1].
AKI rarely happens as an isolated event, but generally
occurs in various clinical situations, including intestinal,
hepatic, and cardiac surgery, exposure to radio-contrast, and
sepsis. One of the typical characteristics of AKI is damage to
tubular epithelial cells. Chronic inﬂammation is frequently
noted in patients with CKD. Growing bodies of evidence
indicate that the inﬂammatory response in AKI contributes
to tubular epithelial cell injury through various cellular and
molecular events: production of adhesion molecules by
injured endothelium leading to leukocyte inﬁltration, produc-
tion of inﬂammatory cytokines and chemokines leading to
tubular epithelial cell death and enhancement of inﬂammatory
responses, and production of hemodynamic regulators indu-
cing an alteration in renal blood ﬂow [3,4]. A preexisting injury
produces two opposing consequences for subsequent injury,
one beneﬁcial and the other harmful. A preexisting injury
either increases or reduces the vulnerability of the organ to
subsequent injury, and this is the case even for remote organs.
These effects are associated with a number of systemic and
local factors (e.g., cytokines, chemokines, and hemodynamic
regulators) that can inﬂuence the functions and microenviron-
ments of the organs. Therefore, it is presumed that preexisting
mild inﬂammation makes kidney epithelial cells more vulner-
able to subsequent injury.132/$ - see front matter & 2014. The Korean Society of Nephrology. Pub
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Skott and colleagues [5] investigated the response of organs
(kidney, liver, and lung) after intestinal ischemia/reperfusion
(I-IR)-induced AKI in rats with or without CKD. To mimic AKI
in patients with CKD, the authors established a two-stage
rodent model. This model involved a 5/6 nephrectomy-
induced CKD followed by an I-IR-induced AKI. In this study,
Skott et al [5] delineated CKD based on an increased serum
creatinine concentration at the beginning of I-IR, as serum
creatinine concentration is generally used as a marker of
preexisting CKD. The authors found that the serum creatinine
levels after I-IR were higher in the 5/6 nephrectomized rats
than in the nonnephrectomized rats. This ﬁnding is consistent
with previous reports by that group, which showed that
preexisting CKD induced by 5/6 nephrectomy worsens the
outcome of AKI induced by I-IR [6]; this supports the notion
that CKD is a risk factor for AKI.
Patients suffering from CKD present notable inﬂammatory
features, such as higher levels of proinﬂammatory cytokines
and ﬁbrotic lesions in the kidney and plasma in comparison to
healthy individuals [4]. Skott et al [5] observed higher levels of
cytokines in the kidneys of 5/6 nephrectomized rats prior to
I-IR than in nonnephrectomized rats. After I-IR, in the kidneys
of 5/6 nephrectomized rats (but not in their livers or lungs),
they observed higher levels of interleukin (IL)-1β and RANTES
(but not IL-10 or monocyte chemoattractant protein-1) com-
pared to nonnephrectomized rats [5]. These results suggest
that the local inﬂammatory response in CKD kidneys differs
from that in healthy kidneys. In addition, they found that α-
melanocyte-stimulating hormone (a neuropeptide with broad
anti-inﬂammatory properties) treatment did not prevent I-IR-
induced increases of serum creatinine or cytokine production
in the kidney [5]. This is in contrast to previous studies, which
demonstrated that α-melanocyte-stimulating hormone pre-
vented AKI induced by kidney injury as well as AKI induced
secondarily by sepsis or endotoxins [1,5,7]. As discussed by
Skott et al [5], the difference between their results and those of
other researchers [6] may be associated with differences in
their experimental settings. However, this study raised ques-
tions about the role of the preexisting local inﬂammatory
response in the enhanced vulnerability of CKD kidneys to
subsequent AKI-inducing injury.lished by Elsevier. This is an open access article under the CC BY-NC-ND
Editorial / Kidney Res Clin Pract 33 (2014) 71–7272In conclusion, the work of Skott et al [5] has taken an
important step toward understanding the relationship
between CKD and AKI. However, the mechanisms underlying
the inﬂuence of preexisting CKD on AKI remain unclear. This
may be attributable to the variety of deﬁnitions for CKD, the
complexity of CKD progression, which makes it difﬁcult to
compare results between clinical studies, and the dearth
of experimental models for CKD. To better understand the
role of CKD as a risk factor for AKI and the underlying
mechanisms of AKI development in patients with CKD, we
must develop a better model to overcome the differences
between clinics and experiments.Conﬂicts of interest
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